Latest Headlines

Latest Headlines

Bayer Healthcare posts big growth in Asia Pacific

Bayer Healthcare said it expects Asia sales to grow to 11 billion euros by 2015, with 6 billion of that coming from the China region.

Bayer, Novartis circle Pfizer's animal health unit

Pfizer's ($PFE) animal health unit may not be to Sanofi's ($SNY) taste, but Bayer and Novartis ($NVS) appear to have an appetite for it. Sources close to the process tell Reuters that Bayer...

Bayer cuts debt for freedom to make 'significant' acquisition

Bayer will cut its debt this year to €6 billion, or $8 billion, to give it more financing options as it looks for M&A targets.

Bayer CEO Dekkers says price cuts threaten R&D

Bayer CEO Marijn Dekkers totted up a $2.7 billion price tag to research and develop the new anticoagulant Xarelto. And he's warning tight-fisted payers that the more they squeeze drug companies...

FDA puts Xarelto's ACS indication on fast track

The FDA has opened up the fast lane for Bayer  and Johnson & Johnson's ($JNJ) new blood thinner Xarelto.

Finding study flaws, EMA backpedals on Trasylol suspension

European regulators are second-guessing their decision to suspend the Bayer heart-surgery drug Trasylol. The study that persuaded the European Medicines Agency officials to keep Trasylol off the...

Bayer CEO: Shortsighted price cuts lead to long-term pain

Bayer chief Marijn Dekkers (photo) doesn't mind government interference of a sort. When he moved to Germany from the U.S., he found a strong focus on keeping jobs in Germany. "The system in most

Drugmakers aim to dampen risks in slow-paying countries

At first, the mere fact that troubled European countries were deep in debt to drugmakers was news. Then, it was the mounting size of those pharma debts and that Greece, at least, was paying its drug

Medivation surges as rivals aim at fast-changing prostate cancer market

Shares of Medivation ($MDVN) jumped 17% today after the drug developer confirmed some promising Phase III data on the closely-watched prostate cancer therapy MDV3100 and added some reassuring numbers

Yaz plaintiffs ask judge to weigh alleged FDA conflicts

Plaintiffs in the Yaz and Yasmin litigation are asking U.S. District Judge David Herndon to check out evidence of possible conflicts-of-interest on an FDA advisory panel that considered the pills'